A 69-year-old man presented with a 2-year history of changes in bowel habits, including abdominal cramps, constipation, and ...

Oncoinvent Announces Publication of Phase 1 Study Results for Radspherin® in Ovarian Cancer in Gynecologic Oncology  Oslo, Norway, 8 December 2025 - Oncoinvent, a clinical stage, radiopharmaceutical ...

The total pancreatic cancer market size is expected to increase in the 7MM during the forecast period, driven by ongoing ...

India is witnessing a sharp rise in colon cancer among people in their 20s and 30s. Doctors report aggressive tumours, late ...

Preclinical studies indicate that cavity-resident macrophages in the peritoneal and pleural spaces contribute to immunosuppression and cancer ...

ANDRE ONANA will NOT feature at the African Cup of Nations in the latest devastating twist for the goalkeeper, according to ...

During a live event, Yelena Y. Janjigian, MD, moderated a discussion on how to use PD-L1 CPS status when considering ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced ...

Specialty Surgical Oncology Hospital (SSO), a chain of surgical cancer hospitals in Western India, has raised 2.8 million dollars in funding from the Everhope Oncology platform, which is backed by ...

An update from BerGenBio ASA ( ($BRRGF) ) is now available. Oncoinvent has published promising 12-month data from its Phase 1 study on the use of ...

Philadelphia, PA, USA, December 9, 2025, First Patient Enrolled in GOG-3133/ FRAmework-01 Phase 3 Study Evaluating Sofetabart ...

FZOCUS-1 assessed the safety and efficacy of fuzuloparib alone and in combination with apatinib for patients with newly diagnosed or advanced ovarian cancer.